These episodes are known as migraine attacks.Migraine affects up to 12% of the global population and is the second leading ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

Learn the key differences between stroke and migraine symptoms, from onset speed to pain patterns, and know exactly when to ...

This type of migraine is more common in people over the age of 50 and can happen to people who have had migraines before as ...

Atogepant vs placebo for the preventative treatment of migraine alleviated migraine symptoms across 3 clinical trials on day 1.

Researchers found that changes in the brain’s activity start appearing at what’s known as the premonitory phase, which begins hours to days before an attack (see ‘Migraine is cyclical’).

Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.

would seem to be ideally placed to modulate this nociceptive pathway and relieve migraine, but particularly the headache phase. This review will discuss how the TCC, rather than other more ...

The drug – a new dry powder intranasal formulation of the old migraine therapy dihydroergotamine mesylate (DHE) – showed a trend towards improvements in pain and other symptoms in the phase 3 ...